enVVeno Medical Corporation - SIC # 3840 -

Ticker Exchange SIC # Website Latest Ticker
NVNO Nasdaq 3840 www.envveno.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for enVVeno Medical Corporation

Companies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In Growth - Jun 26th, 2025 9:31 am
Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting - Jun 6th, 2025 6:05 am
enVVeno Medical Appoints Jennifer Bright as Chief Financial Officer - May 19th, 2025 6:05 am
Three-Year VenoValve(R) First-in-Human Trial Data Published in the Annals of Vascular Surgery - May 13th, 2025 6:45 am
enVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H24 - May 1st, 2025 6:05 am
VenoValve to be Featured During Presentation at the 47th Annual Charing Cross Symposium - Apr 23rd, 2025 6:00 am
enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment - Apr 16th, 2025 6:30 am
The Impact of the VenoValve(R) on Patients with Primary and Secondary Chronic Venous Insufficiency (CVI) to be Presented at the Society for Clinical Vascular Surgery 52nd Annual Symposium - Mar 31st, 2025 7:00 am
enVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25 - Feb 28th, 2025 6:00 am
enVVeno Medical Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - Feb 19th, 2025 7:00 am
One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum - Feb 19th, 2025 6:45 am
Interim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting - Feb 7th, 2025 7:00 am
enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe - Dec 16th, 2024 6:50 am
enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website - Nov 27th, 2024 6:30 am
enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium - Nov 20th, 2024 6:30 am
enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval - Nov 19th, 2024 6:15 am
enVVeno Medical Reports Third Quarter 2024 Financial Results and Confirms Guidance for Release of Definitive VenoValve Data in November and Completion of FDA Premarket Approval Application for VenoValve in Q4 of this Year - Oct 31st, 2024 6:35 am
enVVeno Medical Successfully Initiates 6-Month Pre-Clinical GLP Study Evaluating enVVe(R) - Oct 28th, 2024 6:30 am
enVVeno Medical Corporation Announces Pricing of $15.0 Million Public Offering - Sep 26th, 2024 8:20 pm
enVVeno Medical Corporation Announces Proposed Public Offering - Sep 26th, 2024 2:05 pm